Lactate dehydrogenase is a serum prognostic factor in clinically regional lymph node-positive prostate cancer

LEANDRO BLAS; MASAKI SHIOTA; SHIGETOMO YAMADA; KOSUKE IEIRI; SHOHEI NAGAKAWA; SHIGEHIRO TSUKAHARA; TAKASHI MATSUMOTO; EIJI KASHIWAGI; ARIO TAKEUCHI; JUNICHI INOKUCHI; KEN ICHIRO SHIGA; AKIRA YOKOMIZO; MASATOSHI ETO

doi:10.21873/anticanres.15183

Lactate dehydrogenase is a serum prognostic factor in clinically regional lymph node-positive prostate cancer

LEANDRO BLAS, MASAKI SHIOTA, SHIGETOMO YAMADA, KOSUKE IEIRI, SHOHEI NAGAKAWA, SHIGEHIRO TSUKAHARA, TAKASHI MATSUMOTO, EIJI KASHIWAGI, ARIO TAKEUCHI, JUNICHI INOKUCHI, KEN ICHIRO SHIGA, AKIRA YOKOMIZO, MASATOSHI ETO

Research output: Contribution to journal › Article › peer-review

3 Citations (Scopus)

Abstract

Background/Aim: Currently, there is no established prognostic serum parameter except PSA in clinically regional lymph node-positive prostate cancer. The aim of this study was to identify serum prognostic factors in clinically regional lymph node-positive prostate cancer. Patients and Methods: Patients diagnosed with regional lymph node-positive prostate cancer between 2008 and 2017 were included. The prognostic value of serum parameters for progression-free survival (PFS) and overall survival (OS) was investigated. Results: Univariate and multivariate analyses showed a statistically significant increased hazard risk for PFS and OS for men with lactate dehydrogenase (LDH) ≥230 IU/l at diagnosis. PFS at 5 years for patients with high and low LDH levels were 69.9% (95% CI=56.8-79.8%) and 18.9% (95% CI=1.23-53.2%), respectively (p=0.003). OS at 5 years for low and high LDH levels were 89.2% (95% CI=78.6-94.7%) and 46.3 (95% CI=11.2-76.2%), respectively (p=0.006). Conclusion: This study shows that LDH is an independent predictor of PFS and OS in patients with regional lymph node metastatic prostate cancer.

Original language	English
Pages (from-to)	3885-3889
Number of pages	5
Journal	Anticancer research
Volume	41
Issue number	8
DOIs	https://doi.org/10.21873/anticanres.15183
Publication status	Published - Aug 2021

All Science Journal Classification (ASJC) codes

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.21873/anticanres.15183

Cite this

BLAS, LEANDRO., SHIOTA, MASAKI., YAMADA, SHIGETOMO., IEIRI, KOSUKE., NAGAKAWA, SHOHEI., TSUKAHARA, SHIGEHIRO., MATSUMOTO, TAKASHI., KASHIWAGI, EIJI., TAKEUCHI, ARIO., INOKUCHI, JUNICHI., SHIGA, KEN. ICHIRO., YOKOMIZO, AKIRA., & ETO, MASATOSHI. (2021). Lactate dehydrogenase is a serum prognostic factor in clinically regional lymph node-positive prostate cancer. Anticancer research, 41(8), 3885-3889. https://doi.org/10.21873/anticanres.15183

BLAS, LEANDRO, SHIOTA, MASAKI, YAMADA, SHIGETOMO, IEIRI, KOSUKE, NAGAKAWA, SHOHEI, TSUKAHARA, SHIGEHIRO, MATSUMOTO, TAKASHI, KASHIWAGI, EIJI, TAKEUCHI, ARIO, INOKUCHI, JUNICHI, SHIGA, KENICHIRO, YOKOMIZO, AKIRA & ETO, MASATOSHI 2021, 'Lactate dehydrogenase is a serum prognostic factor in clinically regional lymph node-positive prostate cancer', Anticancer research, vol. 41, no. 8, pp. 3885-3889. https://doi.org/10.21873/anticanres.15183

@article{35ecac63f14843849bafcc95476fdf79,

title = "Lactate dehydrogenase is a serum prognostic factor in clinically regional lymph node-positive prostate cancer",

abstract = "Background/Aim: Currently, there is no established prognostic serum parameter except PSA in clinically regional lymph node-positive prostate cancer. The aim of this study was to identify serum prognostic factors in clinically regional lymph node-positive prostate cancer. Patients and Methods: Patients diagnosed with regional lymph node-positive prostate cancer between 2008 and 2017 were included. The prognostic value of serum parameters for progression-free survival (PFS) and overall survival (OS) was investigated. Results: Univariate and multivariate analyses showed a statistically significant increased hazard risk for PFS and OS for men with lactate dehydrogenase (LDH) ≥230 IU/l at diagnosis. PFS at 5 years for patients with high and low LDH levels were 69.9% (95% CI=56.8-79.8%) and 18.9% (95% CI=1.23-53.2%), respectively (p=0.003). OS at 5 years for low and high LDH levels were 89.2% (95% CI=78.6-94.7%) and 46.3 (95% CI=11.2-76.2%), respectively (p=0.006). Conclusion: This study shows that LDH is an independent predictor of PFS and OS in patients with regional lymph node metastatic prostate cancer.",

author = "LEANDRO BLAS and MASAKI SHIOTA and SHIGETOMO YAMADA and KOSUKE IEIRI and SHOHEI NAGAKAWA and SHIGEHIRO TSUKAHARA and TAKASHI MATSUMOTO and EIJI KASHIWAGI and ARIO TAKEUCHI and JUNICHI INOKUCHI and SHIGA, {KEN ICHIRO} and AKIRA YOKOMIZO and MASATOSHI ETO",

year = "2021",

month = aug,

doi = "10.21873/anticanres.15183",

language = "English",

volume = "41",

pages = "3885--3889",

journal = "Anticancer research",

issn = "0250-7005",

publisher = "International Institute of Anticancer Research",

number = "8",

}

TY - JOUR

T1 - Lactate dehydrogenase is a serum prognostic factor in clinically regional lymph node-positive prostate cancer

AU - BLAS, LEANDRO

AU - SHIOTA, MASAKI

AU - YAMADA, SHIGETOMO

AU - IEIRI, KOSUKE

AU - NAGAKAWA, SHOHEI

AU - TSUKAHARA, SHIGEHIRO

AU - MATSUMOTO, TAKASHI

AU - KASHIWAGI, EIJI

AU - TAKEUCHI, ARIO

AU - INOKUCHI, JUNICHI

AU - SHIGA, KEN ICHIRO

AU - YOKOMIZO, AKIRA

AU - ETO, MASATOSHI

PY - 2021/8

Y1 - 2021/8

N2 - Background/Aim: Currently, there is no established prognostic serum parameter except PSA in clinically regional lymph node-positive prostate cancer. The aim of this study was to identify serum prognostic factors in clinically regional lymph node-positive prostate cancer. Patients and Methods: Patients diagnosed with regional lymph node-positive prostate cancer between 2008 and 2017 were included. The prognostic value of serum parameters for progression-free survival (PFS) and overall survival (OS) was investigated. Results: Univariate and multivariate analyses showed a statistically significant increased hazard risk for PFS and OS for men with lactate dehydrogenase (LDH) ≥230 IU/l at diagnosis. PFS at 5 years for patients with high and low LDH levels were 69.9% (95% CI=56.8-79.8%) and 18.9% (95% CI=1.23-53.2%), respectively (p=0.003). OS at 5 years for low and high LDH levels were 89.2% (95% CI=78.6-94.7%) and 46.3 (95% CI=11.2-76.2%), respectively (p=0.006). Conclusion: This study shows that LDH is an independent predictor of PFS and OS in patients with regional lymph node metastatic prostate cancer.

AB - Background/Aim: Currently, there is no established prognostic serum parameter except PSA in clinically regional lymph node-positive prostate cancer. The aim of this study was to identify serum prognostic factors in clinically regional lymph node-positive prostate cancer. Patients and Methods: Patients diagnosed with regional lymph node-positive prostate cancer between 2008 and 2017 were included. The prognostic value of serum parameters for progression-free survival (PFS) and overall survival (OS) was investigated. Results: Univariate and multivariate analyses showed a statistically significant increased hazard risk for PFS and OS for men with lactate dehydrogenase (LDH) ≥230 IU/l at diagnosis. PFS at 5 years for patients with high and low LDH levels were 69.9% (95% CI=56.8-79.8%) and 18.9% (95% CI=1.23-53.2%), respectively (p=0.003). OS at 5 years for low and high LDH levels were 89.2% (95% CI=78.6-94.7%) and 46.3 (95% CI=11.2-76.2%), respectively (p=0.006). Conclusion: This study shows that LDH is an independent predictor of PFS and OS in patients with regional lymph node metastatic prostate cancer.

UR - http://www.scopus.com/inward/record.url?scp=85111711340&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85111711340&partnerID=8YFLogxK

U2 - 10.21873/anticanres.15183

DO - 10.21873/anticanres.15183

M3 - Article

C2 - 34281850

AN - SCOPUS:85111711340

SN - 0250-7005

VL - 41

SP - 3885

EP - 3889

JO - Anticancer research

JF - Anticancer research

IS - 8

ER -

Lactate dehydrogenase is a serum prognostic factor in clinically regional lymph node-positive prostate cancer

Abstract

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this